Moderna To Supply Additional COVID-19 Vaccine Doses To COVAX Alliance

by Vandana Singh, Benzinga Editor

October 29, 2021 1:07 PM | 1 min read |

Moderna Inc MRNA has announced an agreement with Gavi, the Vaccine Alliance, to supply up to 116.5 million doses of its COVID-19 vaccine to be delivered in Q2 of 2022.
The exercise of these options for additional doses represents an increase from an earlier agreement for 60 million doses.
As per the advance purchase agreement signed on behalf of the COVAX Facility, Gavi retains the option to procure 233 million additional doses in 2022 for a potential total of 500 million doses between 2021 and 2022 under the agreement.
All doses are offered at Moderna's lowest tiered price.
The agreement covers the 92 Gavi COVAX Advance Market Commitment low- and middle-income countries.
Price Action: MRNA shares are down 0.97% at $344.56 during the market session on the last check Friday.
Image by Spencer Davis from Pixabay

Posted In: Biotech Government News Health Care Movers Trading Ideas General Briefs COVID-19 Coronavirus COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.